VVOSEarnings o’clock
Vivos Therapeutics is doing the classic public-company dance: file the results, then hop on a call and explain the numbers like everyone’s reading over its shoulder. The company said it plans to release full-year 2025 financial results after market close on April 15, 2026, followed by a conference call at 5:00 p.m. ET.
Why you should care
This isn’t the earnings release itself, so there’s no new revenue miss or surprise beat to chew on yet. But for a small-cap name like Vivos, the schedule matters because the market tends to get jumpy around:
- growth trends in its sleep-disorder business
- margin progress and cash burn
- any operational update management slips in between the lines
The company’s pitch, in plain English
Vivos sells medical device and healthcare services products aimed at breathing-related sleep disorders, especially obstructive sleep apnea. In other words: it’s trying to make a pretty big promise in a pretty crowded market, which means the numbers and the commentary have to do the heavy lifting.
Big picture
Today’s announcement is basically the appetizer before the main course. If the results show improving demand or better economics, investors may get a reason to stay awake through the call. If not, well, the stock may hit snooze.